Revenue rose 15% to KRW 64.9 billion in 2024, with net income up 77% to KRW 6.3 billion, driven by Bio-Chemical division growth and improved margins. The company completed a new GMP plant and fully repaid convertible bonds, strengthening its financial position.
Original document:
This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.